Earnings call transcript: PolyNovo posts strong FY 2026 growth as shares fall 8%

PolyNovo reported FY2026 NovoSorb sales of AUD 138m (+16.7% reported / +21.3% constant currency) and adjusted EBITDA of AUD 13.4m (+50% YoY), with operating cash flow rising to AUD 23.1m (from AUD 3.1m) and gross margin holding at 89%. Despite the strong operating/cash metrics, shares fell 8.02% to AUD 0.975 as investors weighed valuation concerns and a Financial Health Score marked “WEAK,” alongside expected gross margin drag of ~1% to 1.5% when the new Port Melbourne facility ramps in around March 2027. Management reaffirmed FY2027 priorities, including SynPath US outpatient launch preparations and maintaining PMA submission timing for end of calendar 2027 (with FDA review expected around ~12 months post-submission).

Analysis

The selloff is telling us the market is discounting a durability problem, not a single quarter problem. PNV is transitioning from a burn-driven story to a broader complex-wound franchise, and that matters because the valuation gap versus larger med-tech peers should compress only if account penetration and outpatient adoption stay sticky after the initial enthusiasm fades. The immediate read-through is mixed for synthetic wound-care peers like RCEL: if PNV keeps proving surgeon preference and reimbursement navigation, smaller rivals face a tougher share-take fight in the higher-acuity segment where evidence actually matters.

The bigger second-order issue is that the next leg of the bull case is more about commercialization discipline than product novelty. The new facility and SynPath rollout create a 6-18 month margin headwind/optionality tradeoff: near term, investors will focus on whether gross margin stays in the 90%+ range through the transition; over time, the real upside comes from whether outpatient codes and hospital relationships convert into a lower-friction sales model. If growth slows to high-single digits while fixed costs rise, the multiple can compress fast despite good absolute numbers.

Contrarian view: consensus is probably over-focused on the PMA milestone and under-focused on the already-visible operating leverage in existing accounts. The most important falsifier is not the regulatory date, but whether U.S. constant-currency growth re-accelerates over the next 1-2 quarters after the July momentum. If it doesn’t, the current premium is hard to defend; if it does, the recent weakness is likely a setup rather than a warning.

Key Decisions for Investors

• Hold off on chasing PNV immediately; wait 1-2 weeks for post-print price discovery and only add if the stock reclaims the prior support zone on improving volume, which would confirm the market is absorbing the guidance skepticism.
• For a relative-value expression, go long PNV / short RCEL over the next 3-6 months: PNV has the cleaner evidence moat and better operating leverage, while RCEL is more exposed to channel and reimbursement friction in synthetic skin substitutes.
• Set an alert on PNV quarterly U.S. growth and gross margin: if constant-currency U.S. sales slip below the low-teens or gross margin drops materially before the facility transition, the thesis shifts from temporary skepticism to decelerating fundamentals.
• If you want to own the 12-18 month option value, prefer a staggered equity entry over calls; the catalyst path is binary but long-dated, and implied volatility is likely to stay cheap until the PMA window gets closer.